JP2020532955A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532955A5
JP2020532955A5 JP2020506983A JP2020506983A JP2020532955A5 JP 2020532955 A5 JP2020532955 A5 JP 2020532955A5 JP 2020506983 A JP2020506983 A JP 2020506983A JP 2020506983 A JP2020506983 A JP 2020506983A JP 2020532955 A5 JP2020532955 A5 JP 2020532955A5
Authority
JP
Japan
Prior art keywords
nucleic acid
stranded nucleic
chemically modified
acid molecule
modified double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020506983A
Other languages
English (en)
Japanese (ja)
Other versions
JP7820909B2 (ja
JP2020532955A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045671 external-priority patent/WO2019032619A1/en
Publication of JP2020532955A publication Critical patent/JP2020532955A/ja
Publication of JP2020532955A5 publication Critical patent/JP2020532955A5/ja
Priority to JP2023146785A priority Critical patent/JP2024028231A/ja
Application granted granted Critical
Publication of JP7820909B2 publication Critical patent/JP7820909B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020506983A 2017-08-07 2018-08-07 化学修飾されたオリゴヌクレオチド Active JP7820909B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023146785A JP2024028231A (ja) 2017-08-07 2023-09-11 化学修飾されたオリゴヌクレオチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762542043P 2017-08-07 2017-08-07
US62/542,043 2017-08-07
US201762558183P 2017-09-13 2017-09-13
US62/558,183 2017-09-13
PCT/US2018/045671 WO2019032619A1 (en) 2017-08-07 2018-08-07 CHEMICALLY MODIFIED OLIGONUCLEOTIDES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146785A Division JP2024028231A (ja) 2017-08-07 2023-09-11 化学修飾されたオリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2020532955A JP2020532955A (ja) 2020-11-19
JP2020532955A5 true JP2020532955A5 (cg-RX-API-DMAC7.html) 2021-08-26
JP7820909B2 JP7820909B2 (ja) 2026-02-26

Family

ID=65271710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020506983A Active JP7820909B2 (ja) 2017-08-07 2018-08-07 化学修飾されたオリゴヌクレオチド
JP2023146785A Pending JP2024028231A (ja) 2017-08-07 2023-09-11 化学修飾されたオリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023146785A Pending JP2024028231A (ja) 2017-08-07 2023-09-11 化学修飾されたオリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20200215113A1 (cg-RX-API-DMAC7.html)
EP (1) EP3664817A4 (cg-RX-API-DMAC7.html)
JP (2) JP7820909B2 (cg-RX-API-DMAC7.html)
CN (1) CN111201024A (cg-RX-API-DMAC7.html)
AU (1) AU2018313149B2 (cg-RX-API-DMAC7.html)
CA (1) CA3070747A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019032619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
JP6772062B2 (ja) * 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. 癌の免疫療法
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
CA3160657A1 (en) * 2019-11-08 2021-05-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN112266911B (zh) * 2020-08-27 2022-07-22 清华大学 核酸分子
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
WO2023015265A2 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023130021A1 (en) * 2021-12-30 2023-07-06 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved delivery properties
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック, インコーポレイテッド 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
WO2024064769A1 (en) * 2022-09-21 2024-03-28 Phio Pharmaceuticals Corp. Induction of stem-like activated t cells
AU2023472921A1 (en) * 2023-11-08 2026-05-21 Phio Pharmaceuticals Corp. Intratumoral targeting of pd-1
CN122477046A (zh) * 2023-11-28 2026-07-28 菲奥医药公司 利用RNAi的增强的组合免疫检查点抑制治疗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP2342340A1 (en) * 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010039543A2 (en) * 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2010090762A1 (en) * 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9957558B2 (en) * 2011-04-28 2018-05-01 Life Technologies Corporation Methods and compositions for multiplex PCR
JP6772062B2 (ja) * 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. 癌の免疫療法
EP3180359A1 (en) * 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
CN107921147B (zh) * 2015-05-05 2021-12-24 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用
CA2998589A1 (en) * 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.

Similar Documents

Publication Publication Date Title
US20230285538A1 (en) Efficacious mrna vaccines
JP6993649B2 (ja) 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途
US20210340543A1 (en) Non-coding immunomodulatory dna construct
US20220387585A1 (en) Adoptive cell therapy using spherical nucleic acids (snas)
JP2023179428A (ja) メッセンジャーリボ核酸(mRNA)をコードする安定化された核酸
JP6083571B2 (ja) 自己ゲル化核酸
US20200291394A1 (en) Conjugation of peptides to spherical nucleic acids (snas) using traceless linkers
JP2010515464A (ja) Hiv細胞表面受容体の標的化不活性化のための組成物および方法
HUE026020T2 (en) Preparation for inhibiting gene expression and its uses
JP2023501445A5 (cg-RX-API-DMAC7.html)
CA2632940A1 (en) Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
AU2018247308A1 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP2024529025A5 (cg-RX-API-DMAC7.html)
CN108431228A (zh) Tlr抑制性寡核苷酸及其用途
KR101749230B1 (ko) 지질-dna 및 면역 조절 물질을 포함하는 자기조립 나노구조체, 및 이를 유효성분으로 포함하는 암, 감염 질환 또는 면역 질환의 치료 또는 예방용 약제학적 조성물
CN108251421A (zh) 抑制人和动物中COL1A1基因表达的siRNA、包含其的组合物及其应用
CN106341978A (zh) 用于自身免疫疗法的树突细胞的基于微球的递送和离体操作